

IF



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT EXAMINING OPERATION

Applicants: Bandi Parthasaradhi Reddy, et al.

Serial No: 10/571,744

Group Art Unit:

Filed: March 13, 2006

Examiner:

Att. Docket No.: H1089/20032

Confirmation No.:

For: CRYSTALLINE ALFUZOSIN BASE

IDS CERTIFICATION STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached Form PTO/SB/08a. Unless otherwise indicated herein, one copy of each reference is attached. No copies of U.S. patents or U.S. patent application publications are attached. 37 CFR § 1.98(a)(2)(ii). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the references are prior art with respect to this application.

This Information Disclosure Statement is being filed within three months of the filing date of a national application other than a CPA under 37 CFR § 1.53(d), within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application, before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of an RCE under 37 CFR § 1.114. No certification or fee is required. 37 CFR § 1.97(b).

Application No. 10/571,744

IDS Certification Statement dated September 20, 2006

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOV, LTD.


September 20, 2006

Please charge or credit our Account
No. 03-0075 as necessary to effect
entry and/or ensure consideration of
this submission.

By

Robert S. Silver
Registration No. 35,681
Customer No. 03000
(215) 567-2010
Attorneys for Applicant(s)

Please type a plus sign (+) inside this box ☐



Substitute for PTO/SB/O8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known			
				Application Number		10/571,744	
				Filing Date		March 13, 2006	
				First Named Inventor		Reddy Bandi Parthasaradhi, et al.	
				Group Art Unit			
				Examiner Name			
				Attorney Docket Number		H1089/20032	
Sheet		1		of		1	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		4,315,007		Phillippe M. Manoury	
		5,545,738		Borrega, et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (If known)			
			GB 2,231,571		Jozsef Relter, et al.		
			WO 2006/090268	A2	Shriram Narendra Josh		
			WO 2006/030449	A1	Bandi Parthasaradhi Reddy		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		PCT INTERNATIONAL SEARCH REPORT DATED JUNE 29, 2005, NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION DATED JUNE 29, 2006	
		SYNTHESIS AND ANTIHYPERTENSIVE ACTIVITY OF A SERIES OF AMINO-6-7-DIMETHOXYQUINAZOLINE DERIVATIVES, J. ORG. CHEM., 1986, VOL. 29, PAGES 19-25	
		J. Org. Chem., 1988, 53, pages 983-991.	

EXAMINER	DATE CONSIDERED
----------	-----------------

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.